Opus Genetics (IRD) Operating Expenses (2010 - 2026)

Opus Genetics (IRD) has reported Operating Expenses for 17 consecutive years, with $16.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 15.54% year-over-year to $16.5 million; the TTM figure through Mar 2026 stood at $55.0 million (down 29.42% YoY), while the FY2025 annual figure was $52.8 million, down 27.74% from the prior year.
• Operating Expenses improved to $16.5 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $42.3 million in Q4 2024 and bottomed at $4.5 million in Q3 2022.
• Historically, Operating Expenses has averaged $11.4 million across 5 years, with a median of $9.4 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 494.54% — and 2025, when it slumped 63.81%.
• Opus Genetics' Operating Expenses stood at $5.6 million in 2022, then gained by 26.24% to $7.1 million in 2023, then jumped by 494.54% to $42.3 million in 2024, then sank by 63.81% to $15.3 million in 2025, then increased by 7.85% to $16.5 million in 2026.
• Business Quant data shows IRD's Operating Expenses at $16.5 million in Q1 2026, $15.3 million in Q4 2025, and $11.4 million in Q3 2025.